A 35-year-old man presents with recurrent oral erosions and painful blisters on the palms and soles for 6 months. Histopathology shows acantholysis with suprabasal clefting and a 'tombstone' appearance of basal cells. Direct immunofluorescence reveals IgG and complement deposits in an intercellular pattern throughout the epidermis. Serum IgG antibodies against desmoglein 1 and desmoglein 3 are both positive. Which of the following is the MOST appropriate next step in management?

Explanation

## Diagnosis and Pathophysiology This patient has **pemphigus vulgaris (PV)**, the most severe form of pemphigus. The clinical and immunological features are pathognomonic: - **Suprabasal acantholysis** with 'tombstone' appearance on histology - **Intercellular IgG deposition** ("tombstone" pattern on DIF) - **Dual seropositivity** (anti-Dsg3 and anti-Dsg1) — characteristic of mucocutaneous PV - **Mucosal involvement** (oral erosions) + **acral and flexural distribution** (palms, soles) ## Management Strategy for Pemphigus Vulgaris **Key Point:** Pemphigus vulgaris requires aggressive immunosuppression from the outset because: 1. Monotherapy with corticosteroids alone carries high relapse rates (50–70% within 1 year) 2. High-dose oral corticosteroids (1–1.5 mg/kg/day) cause significant morbidity over prolonged treatment 3. Early introduction of steroid-sparing agents reduces cumulative steroid exposure and improves long-term outcomes ### Treatment Algorithm ```mermaid flowchart TD A["Pemphigus Vulgaris Diagnosis"]:::outcome --> B{"Severity?"}:::decision B -->|"Mild/Localized"| C["Topical corticosteroids<br/>+ Oral corticosteroids<br/>0.5-1 mg/kg/day"]:::action B -->|"Moderate-Severe<br/>Mucocutaneous"| D["Systemic corticosteroids<br/>1-1.5 mg/kg/day"]:::action D --> E["Add steroid-sparing agent<br/>from Week 2-4"]:::action E --> F["Azathioprine 1-2 mg/kg/day<br/>OR<br/>Mycophenolate mofetil 1-3 g/day"]:::action F --> G["Gradual taper of corticosteroids<br/>over 3-6 months"]:::action G --> H["Continue steroid-sparing agent<br/>for 12-24 months"]:::action H --> I["Remission/Low-dose maintenance"]:::outcome ``` **High-Yield:** The **Pemphigus Disease Area Index (PDAI)** score guides initial therapy: - **PDAI < 10:** Topical corticosteroids ± low-dose oral corticosteroids - **PDAI 10–30:** Oral corticosteroids + early steroid-sparing agent - **PDAI > 30:** High-dose corticosteroids + steroid-sparing agent (current case) ## Why Option 2 (Correct Answer) is Superior | Aspect | Corticosteroid Monotherapy | Corticosteroid + Steroid-Sparing Agent | |--------|---------------------------|----------------------------------------| | **Relapse rate at 1 year** | 50–70% | 15–25% | | **Cumulative steroid dose** | 2–3 g (high toxicity) | 0.5–1 g (reduced toxicity) | | **Adverse effects** | Diabetes, osteoporosis, infections | Manageable with monitoring | | **Time to remission** | 6–12 months | 3–6 months | | **Evidence base** | Older, observational | RCTs support combination therapy | **Clinical Pearl:** Azathioprine and mycophenolate mofetil both have level 1 evidence for steroid-sparing efficacy in PV. Azathioprine is more commonly used in India due to cost and familiarity, but MMF is preferred in patients with TPMT deficiency or those intolerant to azathioprine. ## Monitoring During Combination Therapy 1. **Baseline:** CBC, LFTs, renal function, TPMT status (if azathioprine) 2. **Weekly × 4 weeks:** CBC (azathioprine can cause leukopenia) 3. **Monthly:** CBC, LFTs during maintenance 4. **Serology:** Anti-Dsg3/Dsg1 titers every 3 months (correlate with disease activity) ## Why Other Options Are Suboptimal **Option 1 (Monotherapy at 1 mg/kg/day):** While this is the traditional approach, it is no longer considered optimal for moderate-to-severe PV. Studies show that early addition of a steroid-sparing agent reduces relapse rates by 50% and cumulative steroid toxicity by 60–70%. **Option 4 (Plasmapheresis + rituximab):** These are **second-line or rescue therapies** reserved for: - Corticosteroid-resistant disease - Severe adverse effects from conventional therapy - Fulminant disease with life-threatening complications They are not first-line because they are expensive, require specialized infrastructure (plasmapheresis), and rituximab carries risks of infections and hematologic toxicity. **Mnemonic:** **CASS** — **C**orticosteroids + **A**zathioprine/**S**teroid-sparing agent + **S**low taper = Standard of care for PV. [cite:Harrison 21e Ch 324]